Develops therapies for fibrotic diseases, focusing on small molecule drugs that target nuclear receptors to modulate gene transcription.
Inventiva S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative oral small molecule therapies aimed at addressing significant medical challenges such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Central to its portfolio is Lanifibranor, the company's lead product candidate which has successfully completed a Phase IIb clinical trial designed for treating NASH, a chronic liver disease associated with metabolic disorders.
Additionally, Inventiva S.A. is advancing Odiparcil, another promising therapy that has completed a Phase IIa clinical trial targeting MPS VI subtype disease, a rare genetic disorder. Beyond these pivotal programs, the company maintains an active pipeline of early-stage initiatives spanning oncology and other therapeutic areas, underscoring its commitment to expanding treatment options across diverse medical conditions.
Founded in 2011 and headquartered in Daix, France, Inventiva S.A. operates with strategic collaborations that further bolster its research and development efforts. Collaborative ventures include partnerships with AbbVie focused on autoimmune diseases and Boehringer Ingelheim International GmbH aimed at developing novel treatments for idiopathic pulmonary fibrosis. With a robust scientific foundation and a dedication to innovation, Inventiva S.A. continues to advance its mission of transforming patient care through cutting-edge pharmaceutical advancements.